Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Award amount
$984,242Program and phase
SBIR · Phase IIAward year
2025Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CELLCHORUS INC
- Proposal award date
- 2025-05-01
- Contract end date
- 2027-04-30
- UEI
- LUF6ANBGK7F4
- Solicitation number
- PA23-230
- Topic code
- 100
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Functional signatures of post-infusion CAR T cells for early indication of patient response
- LF-TIMING: Large-scale label-free profiling of cell-cell interactions
- LF-TIMING: Large-scale label-free profiling of cell-cell interactions
- Dynamic single-cell analysis instrument to evaluate immune cell function
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer
Research funding history
8 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $5,813,959. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation